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Abstract Central nervous system aspergillosis is an often
fatal complication of invasive Aspergillus infection. Relevant
disease models are needed to study the pathophysiology of
cerebral aspergillosis and to develop novel therapeutic
approaches. This study presents a model of central nervous
system aspergillosis that mimics important aspects of
human disease. Eleven-day-old non-immunosuppressed
male Wistar rats were infected by an intracisternal injection
of 10 l of a conidial suspension of Aspergillus fumigatus.
An inoculum of 7.18 log10 colony-forming units (CFU)
consistently produced cerebral infection and resulted in
death of all animals (n = 25) within 3–10 days. Median sur-
vival time was 3 days. Histomorphologically, all animals
developed intracerebral abscesses (2–26 per brain) contain-
ing abundant fungal hyphae and neutrophils. Fungal culture
of cortical homogenates yielded maximal growth on day 3
after infection (5.4 log10 CFU/g, n = 15) that declined over
time. Galactomannan concentrations in cortical homogen-
ates, assessed as an index for hyphal burden, peaked on
days 3–5. Fungal infection spread to peripheral organs in
83% of animals. Fungal burden in lung, liver, spleen and
kidney was two orders of magnitude lower than in the
brain. The successful establishment of a model of cerebral
aspergillosis in a non-immunosuppressed host provides the
opportunity to investigate mechanisms of disease and to
develop novel treatment regimens for this commonly fatal
infection.
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Introduction
Invasive aspergillosis is a major cause of illness and death
in immunocompromised subjects, including patients with
hematologic cancers and recipients of bone marrow and
solid-organ transplants. Risk factors are prolonged neutro-
penia, graft-versus-host disease, high-dose corticosteroid
treatment and other immunosuppressive regimens. Cerebral
aspergillosis occurs at a frequency of 14–42% in patients
with acute leukemia or allogeneic stem-cell transplantation
making it the most common organ manifestation of hema-
togenous dissemination from primary foci, usually in the
lungs [16, 24]. Alternatively, cerebral aspergillosis can
arise by direct invasion from adjacent infectious foci e.g.,
sinusitis. The pathophysiology of cerebral aspergillosis is
incompletely understood. Ischemic and hemorrhagic inf-
arcts are thought to result from arteriolitis and arteritis with
fungal thrombosis and obliteration of the vessel lumen.
Cerebral abscesses characterized by necrotic parenchyma, a
paucity of inXammatory cells and fungal hyphae are com-
monly found, but their pathogenesis has remained largely
unknown [30]. Until recently, cerebral aspergillosis was
considered to be universally lethal [16, 24, 30]. Recently
introduced antifungal drugs with enhanced central nervous
system penetration and novel mechanisms of action oVer
promising treatment options. Indeed, the combination of
voriconazole and neurosurgery resulted in complete or par-
tial responses in 28 of 81 patients with central nervous sys-
tem (CNS) aspergillosis [27]. The role of posaconazole and
the echinocandins in the treatment of cerebral aspergillosis
remains to be deWned. Relevant disease models are needed
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to develop improved treatment regimens.
A recently established model of aspergillosis in immu-
nosuppressed mice uses direct intracerebral injection of
conidia to induce cerebral abscesses [3]. This model has
been used successfully for studies on drug eYcacy and dis-
ease progression [4, 5, 6, 8, 14, 15, 29]. However, persistent
pancytopenia induced by the high level of immunosuppres-
sion necessary to establish infection and the signiWcant
systemic disease that likely contributes to mortality may be
considered as the disadvantages of this model.
Building on our experience with experimental CNS
infection in rats, we have established a model of cerebral
aspergillosis in non-immunosuppressed nursing rats that
mimics important aspects of human disease [1, 10, 22, 23,
28]. To allow suYcient time to study disease progression
and potential treatment eVects, CNS infection in untreated
animals was intended to be universally and reproducibly
lethal within several days.
Materials and methods
Fungal inoculum
The strain of Aspergillus fumigatus used for infection was
isolated from a patient with invasive pulmonary aspergillo-
sis. The isolate was cultivated on Sabouraud’s agar plates at
37°C for 3 days [31]. Conidia were harvested by washing
the plates with phosphate-buVered saline (PBS) supple-
mented with 0.05% Tween 80 and Wltering the resulting
suspension through a BD Falcon 40 m nylon cell strainer
(BD Biosciences, Bedford, MA, USA) to eliminate hyphal
fragments and conidial clumps. The concentration of the
resulting stock suspension of predominately single spores
was repeatedly veriWed by culturing serial dilutions on Sab-
ouraud’s agar plates. Colony-forming units (CFU) were
counted after 20 h at 37°C. Three days before infection, the
stock suspension (stored at 4°C) was diluted with 0.05%
Tween 80 in PBS to the desired concentration, which was
veriWed by culture. In addition, the fungal titer of the inocu-
lum was routinely conWrmed by quantitative culture on the
day of infection.
Rats
Nursing Wistar rat pups (Charles River Laboratories, Sulz-
feld, Germany) were kept in groups of four to eight with
their dam for 5 days before the experiments. Water and
food were provided ad libitum during a 12-h day–night
cycle. The animal studies were approved by the Animal
Care and Experimentation Committee of the Kanton of
Bern, Switzerland, and followed National Institutes of
Health guidelines for the performance of animal experi-
ments.
To produce cerebral Aspergillus infection
No immunosuppressive drugs were used. The relative
immaturity of the immune system of infant rats permits
establishment of invasive aspergillosis without iatrogenic
immunosuppression. To produce cerebral Aspergillus
infection, the inoculum was injected into the cisterna
magna of the rats. The procedure that does not produce
structural brain damage was well tolerated by all animals
and no deaths were observed during the Wrst 12 h after
injection. On postnatal day 11, when the rats (n = 97)
weighed 26.5 § 3.9 g, they were infected by a direct intra-
cisternal injection, with a 32-gauge needle of 10 l of saline
containing Aspergillus conidia [1, 10, 22, 23, 28]. In pre-
liminary experiments, the rats (n = 12) were given inocula
of 5.0, 6.0 and 7.0 log10 CFU (n = 4 per group). One animal
of each group was killed on day 4 for quantitative cerebral
fungal culture (resulting in 3.2, 3.4 and 4.6 log10 CFU/g,
respectively) and three out of four were observed for sur-
vival to day 7 after infection when the experiment was cen-
sored. The median survival of animals infected with inocula
·7.0 log10 CFU was 7 days (range 3–7). For an inoculum
of 5.0 log10 CFU survival was 100%.
In the dose Wnding studies, four diVerent inocula of
A. fumigatus conidia were injected: 7.18 log10 CFU (n = 25),
7.3 log10 CFU (n = 9), 7.48 log10 CFU (n = 11) and
7.70 log10 CFU (n = 8). In a pilot experiment, corticoster-
oids were administered immediately after infection in an
attempt to decrease the mortality associated with higher
inocula (n = 18). However, dexamethasone administered at
a dose of 0.5 mg/kg after inoculation of 7.3 log10
CFU (n = 8) or at 4 mg/kg following infection with
7.48 log10 CFU (n = 10) was associated with 100% mortal-
ity within 24 h. Because of the precipitous mortality associ-
ated with corticosteroid use, we decided to limit our study
to animals without iatrogenic immunomodulation.
In an additional group of 14 rats, the kinetics of intrace-
rebral fungal replication during the Wrst 4 days after infec-
tion was studied.
The size of the inoculum used for infection, calculated
to contain 7.18 log10 CFU/10 l was conWrmed by culture
of serial dilution and yielded a growth of 7.17 §
6.54 log10 CFU/10 l (n = 3). Uninfected control animals
were injected with 10 l of sterile saline.
The intracisternal injection was performed by the same
experimenter in all animals. The procedure failed to pro-
duce an infection in 14/111 rats that were excluded from
evaluation. These animals survived to day 11 without clini-
cal signs of infection; they were culture-negative in all
organs studied: brain, lung, liver, kidney and spleen, and123
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brain. Failure to produce infection may result from subcuta-
neous deposition of the inoculum. We observed failures as
isolated occurrences, except in one underperforming exper-
iment where 7 of 14 animals were not infected. Infection
was not produced in 2 of 6 rats with an inoculum of
7.0 log10 CFU, 9 of 48 with an inoculum of 7.18 log10 CFU
(7 of which in one experiment), 1 of 10 with an inoculum
of 7.3 log10 CFU and 2 of 13 with an inoculum of
7.48 log10 CFU. In the absence of a non-invasive method to
discriminate infected from non-infected animals, we retro-
spectively identiWed failure of infection by a comprehensive
analysis of all parameters assessed including disease-free
survival, weight gain, quantitative organ culture, galacto-
mannan determination and histopathology.
After infection, all animals were assessed clinically
twice daily using a scoring system with a range of 1–5
based on activity, time to return from a supine to an upright
position and alertness (5—no signs of disease; 4—slightly
reduced activity, animal turns upright in <5 s; 3—reduced
activity, animal turns upright in >5 and <30 s; 2—loss of
capacity for coordinated and purposeful activity, animal
fails to turn upright; 1—coma). Animals with a score of ·2
were killed for ethical reasons with an overdose of pento-
barbital (100 mg/kg intraperitoneally) and subsequently
perfused via the right cardiac ventricle with ice cold PBS.
In survival studies, the day of death was assigned to the day
the animals were killed for ethical reasons (n = 41); for ani-
mals found dead (n = 21), death was assigned to the same
day.
Fungal cultures
One sagital half brain, the left lung, one kidney, the liver,
and the spleen were weighed, diluted 1:1 (w:v) in PBS,
homogenized in a tissue homogenizer, serially diluted 10¡2
to 10¡4 in PBS, and cultured on Sabouraud’s agar plates.
CFU were counted after 20 h at 37°C. Plates with no
growth after 5 days were considered sterile. The detection
limit was 200 CFU/g of tissue. To better characterize the
early stages of infection, animals infected with 7.18 log10
CFU of A. fumigatus conidia were sacriWced at 1, 2, 3, and
4 days after infection (3 to 4 animals per time point) and
brain homogenates were processed for fungal culture.
Histopathologic examination
The sagittal half brains not used for culture were Wxed for
12 h in 4% formaldehyde in PBS and paraYn embedded.
Coronal sections obtained from the frontal, middle and
dorsal brain regions were stained with Grocott’s modiWed
Gomori and periodic acid-SchiV stain.
Galactomannan determination
Galactomannan concentration was assessed in brain homogen-
ates diluted in 1:40 in PBS according to the manufacturer’s
instruction (Platelia Aspergillus test, Bio-Rad Laboratories
AG, Reinach, Switzerland). Concurrently measured inter-
nal controls and calibrators were used to determine the
galactomannan index.
Statistical analysis 
Statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., San Diego, USA). Normally dis-
tributed variables (weight) are presented as mean § SD and
were compared using one-way ANOVA followed by the
unpaired student’s t test. Variables that were not normally
distributed (CFU) were compared by the Kruskal–Wallis
test. When the latter yielded a statistically signiWcant value
(P < 0.05), pair-wise comparison was done using the two-
tailed non-parametric Mann–Whitney U test. Survival curves
were analyzed by Kaplan–Meier analysis and compared by
logrank test.
Results
Intracisternal infection of infant rats: dose-Wnding studies
Dose-Wnding studies with inocula ranging from 7.18 to
7.70 log10 CFU of A. fumigatus were performed. The size
of the inoculum showed a dose response with respect to
median survival, which was 2 (range 1–2), 2 (1–6) and 3
(3–10) days for inocula of 7.70 (n = 8), 7.48 (n = 11) and
7.18 log10 CFU (n = 25) of A. fumigatus, respectively
(Fig. 1a). Median survival of rats infected with an inoculum
of 7.3 log10 CFU (n = 9) was 3 (3–11) days (results not
shown).
Figure 1b shows the comparison of inoculum size and
cerebral fungal burden in animals experiencing mortality in
the Wrst 3 days after infection. The number of Aspergillus
CFU recovered from cortical homogenates was propor-
tional to the size of the inoculum. It was 5.58 log10 (4.48–
6.64) for an inoculum of 7.18 log10 CFU, 6.07 log10 (4.95–
6.34) for an inoculum of 7.48 log10, and 6.28 (5.51–6.45)
for an inoculum of 7.70 log10. Fungal recovery for an inoc-
ulum of 7.18 log10 CFU was signiWcantly lower than for the
higher inocula (P = 0.014). Thus, the number of conidia in
the inoculum used for infection determines both, cerebral
fungal burden and mortality. On the basis of this result, we
thought of balancing the severity of disease and mortality
by choosing an inoculum size of 7.18 log10 CFU of A.
fumigatus for further experiments.123
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Three independent experiments with groups of ¸7 animals
using an inoculum of 7.18 log10 CFU of A. fumigatus
resulted in survival curves that were not signiWcantly diVer-
ent (P = ns by log-rank test) with a median survival of
3 days (range 2–10). This similarity of the survival curves
validates the reproducibility and robustness of the present
model of cerebral aspergillosis (Fig. 2).
To study the kinetics of intracerebral fungal replication
during the Wrst 2 days of cerebral Aspergillus infection
when animals appear well and death occurs rarely, and to
correlate the Wndings with the phase when mortality occurs,
rats were killed 1, 2, 3 and 4 days after infection with
7.18 log10 CFU of A. fumigatus (n = 3 or 4 per time point),
and the cerebral fungal burden was determined by culture.
The number of CFU of Aspergillus in cortical homogenates
remained stable over the Wrst 4 days after infection at 5.45
(4.30–5.92) log10 CFU/g. In spite of histological evident
meningitis, in the majority of animals no cerebrospinal Xuid
could be aspirated by puncture of the cisterna magna at any
time after infection.
Clinical manifestations of cerebral aspergillosis
Tremors starting a few hours after infection and lasting a day
(in 84% of animals) were early signs of disease. Nine of 12
animals with tremors persisting on day 2 died on the next day.
In animals infected with 7.18 log10 CFU weight loss starting
2 days prior to death was observed in 52% of animals. On the
day preceding death, 84% of those animals had lost a mean
of 12.5% of their starting weight. On the same day, the
clinical score of all animals infected with an inoculum of
7.18 log10 CFU of A. fumigatus was ¸4 (out of a score of 5),
indicating that CNS aspergillosis proceeded causing only few
signs of disease until the day of death. Circling movements (in
20%), limb weakness (in 12%) and rolling (in 8%), all indi-
cating CNS disease, were observed shortly before death.
Histopathology
Fungal meningitis characterized by an inWltrate with pre-
dominately polymorphonuclear cells (PMN), conidia, and
hyphae was found in 85% of animals. There were no granu-
lomas. Fungal elements and inXammtory cells were concen-
trated around meningeal vessels, many of which contained
thrombotic material and hyphae that had apparently pene-
trated the vessel wall (Fig. 3e, f). A median of 6 superWcial
Fig. 1 a Comparison of the survival curves for non-immunosup-
pressed infant rats infected by intracisternal injection with three diVer-
ent inocula of Aspergillus fumigatus conidia. Survival was inversely
proportional to the size of the inoculum. Results of three independent
experiments are shown. b Comparison of inoculum size and resulting
cerebral fungal burden determined by culture of cortical homogenates
of all animals that died within the Wrst 3 days after infection. The num-
ber of CFU of Aspergillus fumigatus recovered from cortical homo-
genates increases with the size of the inoculum. (n = 15, 9 and 5 for
inocula of 7.18, 7.48 and 7.70 log10 of colony-forming units, respec-
tively)
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Fig. 2 Comparison of the survival curves from three independent
experiments (Exp.) in which infant rats were infected by an intracister-
nal injection of 7.18 log10 CFU of Aspergillus fumigatus conidia.
Infection consistently resulted in 100% mortality within 7–10 days
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Acta Neuropathol (2007) 114:411–418 415and deep cerebral abscesses (range 2–26) containing abun-
dant fungal hyphae and PMN were documented by histo-
morphology in all animals (Fig. 3). More abscesses were
found in animals dying before day 4 (median 6 (2–26),
n = 14) than in those dying on or after day 4 [2.5 (2–5)
n = 6]. Abscess location was cerebellar in 48%, periventric-
ular in 41% and frontal in 11%. No hemorrhages were seen.
Fungal culture
After infection with an inoculum of 7.18 log10 CFU of
A. fumigatus, quantitative fungal culture of cortical homo-
genates yielded maximal growth of 5.58 (4.48–6.64)
log10 CFU/g in animals who died on day 3 after infection
(n = 15; Fig. 4a). This fungal burden is similar to the one
Fig. 3 Histomorphology of animals infected with 7.18 log10 CFU of
Aspergillus fumigatus. Sections (a), (c), (e) and (g) were stained with
periodic-acid SchiV stain; the corresponding adjacent sections (b), (d),
(f) and (h) were stained with Grocott’s modiWed Gomori stain. a, b In
this animal that died on day 4 after infection, three deep abscesses in
the cerebral parenchyma are shown (arrow-heads). The cellular inWl-
trate is closely associated with fungal hyphae, whose orientation sug-
gests outward growth from a center. The abscess highlighted by the
closed arrow-head is enlarged in the insert. The cellular and fungal
inWltrate of the subarachnoid space can be seen as a line of dark stain
following the contour of the cortical hemisphere. c, d Two abscesses
(arrow-heads) have formed at the base of the cerebellum in an animal
that died on day 4 after infection. Both contain abundant PMNs and
fungal elements. e, f Meningitis characterized by a dense inWltrate of
inXammatory cells and fungal elements in the subarachnoid space with
involvement of subarachnoid vessels containing thrombotic material
(arrow-heads) is shown in this animal that died on day 3 after infec-
tion. g, h A cerebral artery of a rat that died on day 3 after infection is
surrounded by a dense inXammatory inWltrate containing abundant
conidia and hyphae. The vessel lumen is obliterated by thrombotic
material containing hyphae (arrow-head)123
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spective of clinical signs between 1 and 4 days after infec-
tion [It was 5.62 (4.70–5.92) log10 CFU/g on day 1; 5.44
(5.26–5.49) log10 CFU/g on day 2; 5.51 (5.32–5.65)
log10 CFU/g on day 3; and 5.53 (4.30–5.53) log10 CFU/g on
day 4). Numbers of Aspergillus CFU in cortical homogen-
ates declined over time to a minimum of 3.7 log10 CFU/g in
the only animal that survived for 10 days.
To measure cerebral fungal burden resulting from Asper-
gillus hyphae, galactomannan concentration in cortical
homogenates was determined (n = 25; Fig. 4b). Galacto-
mannan is an element of the Aspergillus hyphal cell wall
that is absent in conidia. The galactomannan index was
highest in animals that died between 3 and 5 days after
infection and declined in parallel to the CFU counts in ani-
mals that survived beyond 5 days.
No signiWcant correlation was found between CFU
counts and galactomannan from 24 samples (P = 0.2; Per-
son r = 0.26; R squares = 0.06).
To determine the extent of secondary fungal dissemina-
tion from the CNS quantitative fungal culture of visceral
organs and the brain was performed. Fungal infection
spread to at least one peripheral organ in 83% of rats. The
number of Aspergillus CFU in visceral organs of animals
that died on the same day after infection was similar for
liver, lung, kidney and spleen, but was two orders of mag-
nitude lower than in the brain. In animals that died on day 3
(n = 11) after infection with 7.18 log10 CFU of A. fumiga-
tus, all brains were culture positive, all animals had positive
cultures from at least one visceral organ, but only two ani-
mals (18%) had positive fungal cultures from all visceral
organs (Fig. 5).
Similar to the brain, fungal titers in visceral organs
declined over time. Three of 19 animals (that died on days 4,
6 and 7) had sterile cultures from all organs except the brain,
suggesting spontaneous clearance of systemic infection.
Discussion
The development of a model of CNS aspergillosis in ani-
mals without the use of iatrogenic immunosuppression
provides the opportunity to study the pathogenesis of this
disease, the host response and treatment regimens. All the
criteria established for a successful animal model of asper-
gillosis are fulWlled [9]: disease parameters such as cerebral
fungal burden and mortality can be determined by the size
of the fungal inoculum at infection. Mortality most likely
results from cerebral aspergillosis since systemic dissemi-
nation of fungi is controlled by the host response. The
model is robust and reproducible. Infant rats with their
dams are unproblematic and economical to house. In the
Fig. 4 Quantitation of cerebral fungal burden in animals infected with
7.18 log10 CFU of Aspergillus fumigatus. a Fungal culture of all 24
brains yielded growth. Colony-forming unit counts peaked on day 3 at
5.4 log10 colony-forming units/g and declined in animals surviving
longer. b The galactomannan index was highest in animals that died 3–
5 days after infection and declined parallel to the colony-forming units
in animals surviving >5 days
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not needed to protect the animals from opportunistic infec-
tions. Injection of the fungal inoculum into the cisterna
magna caused meningitis involving predominantly PMNs.
The inWltrates with the highest density of fungal elements
and PMNs were found around cerebral vessels, many of
which were obliterated by thrombi containing fungal
hyphae, demonstrating both the angiotropism and propen-
sity of Aspergillus fumigatus to penetrate vessel walls. The
cerebellar and periventricular location of the majority of
fungal abscesses may reXect the postero-anterior concentra-
tion gradient resulting from injection of the infectious coni-
dia in the cisterna magna. Deep abscesses where the radial
distribution of hyphae suggested outward growth from a
center may have originated from hematogenously dissemi-
nated fungal elements or from conidia in the Virchow-
Robbins space of cerebral vessels.
Intracisternal injection of the fungal inoculum mimics
the route of human CNS infection in acute and chronic
invasive Aspergillus sinusitis [13, 19, 21]. In this setting,
meningeal inWltration with inXammatory cells and hyphae
is associated with arteritis and vascular thrombosis result-
ing in ischemic or hemorrhagic necrosis and abscess forma-
tion, similar to the histopathologic Wndings in the present
model. Most cases of human cerebral aspergillosis result
from hematogenous dissemination of fungal elements from
foci of invasive disease most commonly in the lungs. CNS
aspergillosis is characterized by invasion of vascular walls
by hyphae resulting in thrombosis and ischemic infarcts,
where fungi remain almost entirely within the vessels, hem-
orrhagic infarcts and abscesses [2, 16, 18, 30]. In an
autopsy series of 45 patients with CNS aspergillosis, men-
ingitis adjacent to leptomeningeal vessels containing fungal
thrombi was found in virtually all patients [18]. PMNs were
the dominant inXammatory cells present. In organ trans-
plant recipients with CNS aspergillosis, meningitis was
found in 10% of patients in association with necrotizing
cortical lesions [30].
Abscesses composed of a core of necrotic tissue sur-
rounded by an area of hemorrhagic necrosis, inXammatory
cells and hyphae were found in all patients autopsied [18].
Human CNS aspergillosis is well mimicked by our model
with respect to histopathology, rapid disease progression
and universal mortality in the absence of treatment.
In the present model, the time of death was related to
severity of disease: animals dying by day 3 after infection
had higher cerebral fungal concentrations determined by
culture, higher galactomannan levels and a higher number
of cerebral abscesses than animals dying at later time
points. While both hyphae and non-germinated conidia are
measured by culture, galactomannan determination is spe-
ciWc for hyphae, which may explain why there was no sig-
niWcant correlation between the two measures of fungal
burden. Another factor may be underscoring the CFU due
to large colonies.
Most rodent models of invasive aspergillosis require
immunosuppression to produce consistent disease [12, 17,
20, 25, 26]. Immunocompetent mice can be infected by the
i.v. route, but they tend to clear the infection from lung,
liver and spleen, and often from the brains, and die with
high fungal concentrations in their kidneys [11]. Intracere-
bral injection of conidia in non-immunosuppressed mice
either resulted in 100% lethality in the Wrst 2 days or sur-
vival of more than 50% of the animals, depending on the
size of the inoculum that could not be more Wnely titrated
[3]. The model presented here is, to our knowledge, the Wrst
in which consistent cerebral infection is produced in
rodents that are not iatrogenically immunosuppressed or
selected for genetic defects in their immune response. It is
generally accepted that nursing rats between 11 and 21 days
of age are immunologically less competent than adult ani-
mals. However, it is largely unknown in what respects
exactly an infant rat’s immature immune system diVers
from that of an adult animal and to what extent the infant
rats’ immune system becomes more competent as the ani-
mals mature to adolescence.
Infection spreads from the CNS to other organs, but fun-
gal concentrations are two to three orders of magnitude
lower than in the brain and some animals cleared peripheral
infection as early as by day 4 after infection. A potential
advantage of an animal model in a non-immunosuppressed
host is that eYcient treatments may prove curative, an obvi-
ous goal in the patient and one diYcult to achieve in immu-
nocompromised animals [7]. In addition, the absence of
iatrogenic immunosuppression may be beneWcial for stud-
ies of the pathophysiology of aspergillosis. However, cere-
bral aspergillosis in humans most commonly occurs in
patients with at least temporary neutropenia or functionally
impaired neutrophils, which highlights a limitation of the
present model. Pharmacokinetics and pharmacodynamics
of many drugs, including antifungals, diVer between infants
and adults, emphasizing the necessity to monitor drug con-
centrations in serum and target organ when performing
treatment studies with our model.
Compared to the model of cerebral aspergillosis that uses
intracerebral injection of conidia to induce cerebral abscesses
in immunocompromised mice, our model has several advan-
tages: intracisternal infection is minimally traumatic to the
animals, is well tolerated (no deaths related to the procedure
occurred) and does not induce structural brain damage. Sys-
temic dissemination is at a very low level compared to the
cerebral fungal burden, is controlled by the host, and does not
appear to contribute to morbidity and mortality.
This model should be useful for the study of host–patho-
gen interactions and disease mechanisms, and the evaluation
of novel therapeutic approaches to cerebral aspergillosis.123
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